Exact Mass: 392.1366
Exact Mass Matches: 392.1366
Found 127 metabolites which its exact mass value is equals to given mass value 392.1366
,
within given mass tolerance error 0.001 dalton. Try search metabolite list with more accurate mass tolerance error
0.0002 dalton.
7-Ethyl-10-hydroxycamptothecin
SN-38 is a member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself. It has a role as an apoptosis inducer, an EC 5.99.1.2 (DNA topoisomerase) inhibitor, a drug metabolite and an antineoplastic agent. It is a pyranoindolizinoquinoline, a delta-lactone, a tertiary alcohol and a member of phenols. 7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan [DB00762], a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negative Breast Cancer, among others. 7-Ethyl-10-hydroxycamptothecin is a natural product found in Apis cerana with data available. A semisynthetic camptothecin derivative that inhibits DNA TOPOISOMERASE I to prevent nucleic acid synthesis during S PHASE. It is used as an antineoplastic agent for the treatment of COLORECTAL NEOPLASMS and PANCREATIC NEOPLASMS. 7-Ethyl-10-hydroxycamptothecin (SN38) is the active metabolite of irinotecan (an analog of camptothecin - a topoisomerase I inhibitor); it is 1000 times more active than irinotecan itself. In vitro cytotoxicity assays show that the potency of SN-38 relative to irinotecan varies from 2- to 2000-fold. SN38 is metabolized via glucoronidation by UGT1A1. (Wikipedia) 7-Ethyl-10-hydroxycamptothecin (SN38), the active metabolite of irinotecan, exerts a 100-fold to 1000-fold higher effect than irinotecan itself against several tumor cell lines. (PMID: 23233044) Among five chemotherapeutic agents commonly used for breast cancer treatment, only an irinotecan metabolite SN38 showed additive antitumor activity with olaparib. (PMID: 22454224) Metabolism of irinotecan to SN38 is inefficient and subject to considerable patient-to-patient variability. One approach to more controlled administration of the anticancer agent is direct administration of the active SN38. (PMID: 23299391) A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3,4:6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4]. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].
Reglitazar
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
OZESIOWEPLUEAF-QFIPXVFZSA-N
12-Ethyl-9-hydroxycamptothecin is a derivative of Camptothecin. Camptothecin (CPT), a kind of alkaloid, is a DNA topoisomerase I (Topo I) inhibitor with an IC50 of 679 nM[1].
Ala Ala Cys Glu
Ala Ala Glu Cys
Ala Cys Ala Glu
Ala Cys Glu Ala
Ala Asp Gly Met
Ala Asp Met Gly
Ala Glu Ala Cys
Ala Glu Cys Ala
Ala Gly Asp Met
Ala Gly Met Asp
Ala Met Asp Gly
Ala Met Gly Asp
Cys Ala Ala Glu
Cys Ala Glu Ala
Cys Asp Gly Val
Cys Asp Val Gly
Cys Glu Ala Ala
Cys Gly Asp Val
Cys Gly Val Asp
Cys Pro Ser Ser
Cys Ser Pro Ser
Cys Ser Ser Pro
Cys Val Asp Gly
Cys Val Gly Asp
Asp Ala Gly Met
Asp Ala Met Gly
Asp Cys Gly Val
Asp Cys Val Gly
Asp Gly Ala Met
Asp Gly Cys Val
Asp Gly Met Ala
Asp Gly Val Cys
Asp Met Ala Gly
Asp Met Gly Ala
Asp Val Cys Gly
Asp Val Gly Cys
Glu Ala Ala Cys
Glu Ala Cys Ala
Glu Cys Ala Ala
Glu Gly Gly Met
Glu Gly Met Gly
Glu Met Gly Gly
Gly Ala Asp Met
Gly Ala Met Asp
Gly Cys Asp Val
Gly Cys Val Asp
Gly Asp Ala Met
Gly Asp Cys Val
Gly Asp Met Ala
Gly Asp Val Cys
Gly Glu Gly Met
Gly Glu Met Gly
Gly Gly Glu Met
Gly Gly Met Glu
Gly Met Ala Asp
Gly Met Asp Ala
Gly Met Glu Gly
Gly Met Gly Glu
Gly Val Cys Asp
Gly Val Asp Cys
Met Ala Asp Gly
Met Ala Gly Asp
Met Asp Ala Gly
Met Asp Gly Ala
Met Glu Gly Gly
Met Gly Ala Asp
Met Gly Asp Ala
Met Gly Glu Gly
Met Gly Gly Glu
Pro Cys Ser Ser
Pro Ser Cys Ser
Pro Ser Ser Cys
Ser Cys Pro Ser
Ser Cys Ser Pro
Ser Pro Cys Ser
Ser Pro Ser Cys
Ser Ser Cys Pro
Ser Ser Pro Cys
Val Cys Asp Gly
Val Cys Gly Asp
Val Asp Cys Gly
Val Asp Gly Cys
Val Gly Cys Asp
Val Gly Asp Cys
3-(4-Benzoyl-piperazine-1-carbonyl)-8-methoxy-chromen-2-one
Reglitazar
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist